This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Brownbill, P. Articles by Sibley, C. P. Search for Related Content PubMed PubMed Citation Articles by Brownbill, P. Articles by Sibley, C. P. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB NITRIC OXIDE

Vasoactive and Permeability Effects of Vascular Endothelial Growth Factor-165 in the Term in Vitro Dually Perfused Human Placental Lobule

Division of Human Development (P.B., I.P.C., C.P.S.), The Medical School, University of Manchester, Manchester M13 0JH, United Kingdom; Department of Obstetrics and Gynaecology (G.C.M.), Queens University Belfast, School of Medicine, Belfast BT7 1NN, Northern Ireland, United Kingdom; and The Rosie Maternity Hospital (J.C.B.), Addenbrooke’s Hospital, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge DB2 2OO, United Kingdom

Address all correspondence and requests for reprints to: Mr. P. Brownbill, University Research Floor, St. Mary’s Hospital, Hathersage Road, Manchester M13 0JH, United Kingdom. E-mail: paul.brownbill{at}manchester.ac.uk.

Vascular endothelial growth factor (VEGF) is an important vasodilator and effector of permeability in systemic blood vessels. Molecular and tissue culture techniques have provided evidence for its placental synthesis and release. Using an in vitro dual-perfusion model of the term placental lobule from normal pregnancy, we report here the relative secretion of total VEGF, soluble VEGF receptor (VEGFR)-1, and free VEGF into the maternal and fetoplacental circulations of the placenta. We tested the hypothesis that VEGF has vasomotor and permeability effects in the fetoplacental circulation of the human placenta, and we examined the broad intracellular pathways involved in the vasodilatory effect that we found. We show that total VEGF is released into the fetal and maternal circulations in a bipolar fashion, with a bias toward maternal side output. Soluble VEGFR-1 was also secreted into both circulations with bias toward the maternal side. Consequently, free VEGF (12.8 ± 2.4 pg/ml, mean ± SE) was found only in the fetoplacental circulation. VEGF-165 was found to be a potent vasodilator of the fetoplacental circulation (maximum response: 77% of previous steady-state fetal-side inflow hydrostatic pressure after preconstriction with U46619; EC₅₀ = 71 pM). This vasodilatory effect was mediated by the VEGFR-2 receptor and nitric oxide in a manner-independent of the involvement of prostacyclin and the src-family tyrosine kinases. However, nitric oxide could explain only 50% of the vasodilatory effect. Finally, we measured the permeability of the perfused placenta to inert hydrophilic tracers and found no difference in the presence and absence of VEGF.